Has announced its first commercial partnering agreement with international biotechnology company Opsona Therapeutics to develop a new class of Phylomer® drugs targeting inflammatory diseases
21/03/2006 - 21:00
Phylogica Ltd - 16/03/2006
21/03/2006 - 21:00
